Enhancing Survival Through Innovative Immune Modulation

We are a late-stage clinical company developing microbiome therapies to modulate the immune system and improve cancer survival.

See News

Corporate profile

We are a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.

Press Releases

Press Releases

December 10, 2024: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH…
Press Releases
December 5, 2024: MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease
Press Releases
November 26, 2024: MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
Press Releases
November 7, 2024: MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD
Press Releases
November 5, 2024: MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes

See more

Media Coverage

Média

December 10, 2024: France’s MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD – a formal study will read out early next year – Biotech TV

Média
December 5, 2024: The Quest to Turn Human Waste Into Medicine – Bloomberg
Média
October 25, 2024: Le Journal des biotechs : Hervé Affagard, MaaT Pharma (French only)
Media
January 21, 2024: Le microbiote à l’attaque du cancer – Les Echos Investir (French only)
Média
December 21, 2023: MaaT Pharma et Skyepharma mettent en service leur usine de médicaments à base de microbiote – Les Echos (French only)
Média
December 18, 2023: Microbiome-based treatment shows potential in graft-versus-host disease – BioPharma reporter

See more

Videos

R&D Day 2022 replay

On June 7th, 2022, MaaT Pharma hosted its virtual R&D Day to share the latest…
Videos
H.C Wainwright Bioconnect 2022 conference replay
Videos
Investors Webcast – 12/13/21 – Corporate Update
Videos
IABS Bioaster – FMT WEBINAR
Videos
EY : Prix de l’Entrepreneur de l’Année
Videos
Hybridays 2021: Savita BERNAL, Chief Business Officer at MaaT Pharma

Posters

Posters

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe

Posters
MaaT033 to ensure optimal intestinal microbiota to improve survival of patients receiving allo-HSCT: PHOEBUS trial
Posters
PHOEBUS Trial: an international, randomized, double-blind, multicenter phase IIb study evaluating MaaT033, oral allogeneic fecal microbiotherapy, in patients undergoing allo-HSCT to improve overall survival. SEHH Congress (Spanish only)
Posters
Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT034) for clinical testing in combination with immune checkpoint inhibitors in solid tumors
Posters
Pooling of faecal material results in standardized and high taxonomic and functional richness microbiotherapy products
Posters
Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial